Evidence map›Paper›PMID 40830314›Full record

ArticleDigestive diseases and sciences2025

Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.

Jonathan Weng, Madeline Alizadeh, Sonia Friedman

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan WengDepartment of Medicine, Tufts Medical Center, Boston, MA, USA. Jonathan.Weng@tuftsmedicine.org.ORCID http://orcid.org/0000-0002-4051-4722
Madeline AlizadehInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5650-3393
Sonia FriedmanDivision of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2720-4404

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs the prevalence of obesity rises among patients with inflammatory bowel disease (IBD), concerns have emerged regarding the gastrointestinal safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are increasingly used for diabetes and weight management.

methodsWe conducted a retrospective cohort study of adult patients with IBD on GLP-1 RA therapy within a large academic medical system between 2010 and 2024. We compared gastrointestinal adverse events-including ileus or bowel obstruction, bowel surgery, IBD-related hospitalization, and escalation of medical therapy-occurring in the one-year period preceding and following GLP-1 RA exposure, which was defined by at least two prescriptions within 90 days.

resultsAmong 271 patients (median age 62.8 years; 62% female; 64% ulcerative colitis), 80 completed 12 months and an additional 168 completed 6 months of GLP-1 RA therapy. Semaglutide was the most common agent (58%), followed by dulaglutide (28%), tirzepatide (14%), and liraglutide (1%). No significant difference in gastrointestinal adverse event rates was observed between pre- and post-treatment intervals when normalized for exposure time (p ≥ 0.10 for all comparable adverse events). Median BMI declined modestly from 33.8 to 33.4 kg/m

conclusionsGLP-1 RA therapy does not increase gastrointestinal adverse events in patients with IBD over 12 months, supporting its safety in this population.

Indexed as

Gastrointestinal DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInflammatory Bowel DiseasesAdultAgedFemaleGlucagon-Like Peptide 1Glucagon-Like PeptidesHumansImmunoglobulin Fc FragmentsLiraglutideMaleMiddle AgedRecombinant Fusion ProteinsRetrospective StudiesdulaglutideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsSemaglutideDiabetesGastrointestinal adverse eventsGLP-1 receptor agonistInflammatory bowel diseaseObesitySafety

Identifiers

PMID40830314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.